S. Hosseini
Materials Chemistry · with Azimi · 2009–2010
A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Materials Chemistry — 31 citations into it; #6,980 of 11,513 by trust here, #6,473 by citations
- Civil and Structural Engineering — 26 citations into it; #4,201 of 6,160 by trust here, #1,641 by citations
- Metals and Alloys — 17 citations into it; #130 of 267 by trust here, #118 by citations
Whom S. Hosseini trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts S. Hosseini overall
Papers from S. Hosseini's perspective
Ordered by how strongly the researchers S. Hosseini trusts endorse each paper. Same corpus, a different order for every researcher.
- Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. (Clinical Infectious Diseases)
- Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. (Clinical Infectious Diseases)
- Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management (European Respiratory Journal)
- Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. (Clinical Infectious Diseases)
- Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. (New England Journal of Medicine)
- Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. (Clinical Infectious Diseases)
- Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy… (Clinical Infectious Diseases)
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. (The Lancet)
- Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. (New England Journal of Medicine)
- Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. (Clinical Infectious Diseases)